Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I

Overview of attention for article published in Annals of Oncology, March 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

news: 3 news outlets
blogs: 2 blogs
policy: 1 policy source
twitter: 3 X users

patent: 1 patent
wikipedia: 1 Wikipedia page
reddit: 1 Redditor

Readers on

mendeley: 202 Mendeley

So far, Altmetric has seen 3 posts from 2 blogs.

Approval of Elahere Expands Treatment Options for Some Advanced Ovarian Cancers

Cancer Currents: An NCI Cancer Research Blog, 24 Apr 2024

FDA approved mirvetuximab soravtansine-gynx (Elahere) to treat people with advanced, platinum-resistant ovarian cancer whose…

#VisualAbstract: Mirvetuximab soravtansine-gynx compared to chemotherapy in folate receptor alpha-positive platinum resistant ovarian cancer led to improved survival

Physician's Weekly, 29 Dec 2023

1. Mirvetuximab soravtansine-gynx (MIRV) significantly improved progression-free survival, objective response, and overall…

Mirvetuximab soravtansine-gynx compared to chemotherapy in folate receptor alpha-positive platinum resistant ovarian cancer led to improved survival

Physician's Weekly, 19 Dec 2023

1. Mirvetuximab soravtansine-gynx (MIRV), significantly improved progression-free survival, objective response, and overall…

This page shows the most recent blog posts that mention this research output. Click here to find out how to access more activity.